Patent Grant
10098852
The present invention related to a new indication of Monobenzone pharmaceutical composition, especially related to inhibition effect of Monobenzone pharmaceutical composition on a variety of cancer cells.
Monobenzone is a topical bleaching agent for the treatment of hyperpigmentation, such as various spots, age spots, and melanoma. The effect of monobenzone is obvious for the above-mentioned effect. Monobenzone can decompose the melanin in the skin to prevent the generation of melanin in the skin, so that the skin would restore the naturally original skin color. In the meantime. Monobenzone does not destroy melanoma cells. Toxicity of monobenzone is light, and monobenzone is usually made as ointment or liniment as pharmaceuticals. Monobenzone is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
Due to the differences of the clinical use, there is no research present that the Monobenzone has any potential to inhibit cancer cell.
On the other side, cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy. Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. In other words, the new drug development is very difficult.
Therefore, it is a very urgent and important issue that how to develop anti-cancer drugs quickly and reduce the probability of clinical failure for treating various cancers.
In order to solve the above problems, the present invention provides the development of new cancer clinical indications of Monobenzone.
Accordingly, the present invention provides a new indication of Monobenzone. The experimental results showed that the Monobenzone had no toxicity or had little toxicity to normal cells in the present invention. However, the selective effect of Monobenzone between normal cells and cancer cells need to be identified.
The present invention provides a pharmaceutical composition of Monobenzone for treating cancer. The pharmaceutical composition is composed of effective dose of Monobenzone and a pharmaceutical acceptable salt.
In one embodiment of the present invention, the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
In one embodiment of the present invention, the cancer is selected from osteosarcoma, skin cancer and blood cancer.
In one embodiment of the present invention, the pleural-related cancer is lung cancer.
In one embodiment of the present invention, the abdominal-related cancer is selected from bladder cancer, and cervical cancer.
In one embodiment of the present invention, the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
In one embodiment of the present invention, the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
In one embodiment of the present invention, the effective dose of Monobenzone is from 20 mg/kg/day to 500 mg/kg/day.
Cell Culture
Subculture the different types of cancer cells. The cancer cells lines includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. The normal cells used in the control group included kidney cell line (HEK293) and human bronchial epithelial cell line BEAS-2B. (as shown in Table 1).
Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in cell culture plate/flask. Then, the culture medium was added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The cell number was 3000/well and the volume of the culture medium was 100 μl each well.
Cell Viability Analysis
Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well was 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculate the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the Monobenzone drug. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the Monobenzone drug.
The Effect of Monobenzone on Different Cancer Cell Lines
The Inhibition Effect of Monobenzone on Pleural-Related Cancer Cells
This inhibition test of Monobenzone on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650. The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
The Inhibition Effect of Monobenzone on Abdominal-Related Cancer Cell Lines
This inhibition test of Monobenzone on abdominal-related cancer cells were using bladder cancer cell lines TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5). The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.
The Inhibition Effect of Monobenzone on Endocrine-Related Cancer Cell Lines
This inhibition test of Monobenzone on endocrine-related cancer cells were using prostate cancer cell lines PC-3 and LNCap (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8). The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
The Inhibition Effect of Monobenzone on Gastrointestinal Tract-Related Cancer Cell Lines
This inhibition test of Monobenzone on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell lines AsPC-1 and BxPC-3 (Table 12), tongue cancer cell line SAS (Table 13). The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.
The Inhibition Effect of Monobenzone on Other Cancer Cell Lines
This inhibition test of Monobenzone on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
The Experiment Design on Control Group
The Inhibition Effect of Monobenzone on Normal Cells
This inhibition test of Monobenzone on normal cells were using normal kidney cell line HEK293 (Table 16), human fibroblast cell line HFW (Table 17), and normal pulmonary epithelial cell line BEAS-2B (Table 18). The inhibitory tests of Monobenzone were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated The results were shown in Table 16, Table 17 and Table 18.
This inhibition test results of Monobenzone on all kinds of cancer cells were shown in Table 19. As a result in the experiments of the present invention, Monobenzone has a significant inhibitory effect and specificity on various cancer cells. (
Animal Model Test of Gastric Cancer with Dose 100 mg/kg/day and 200 mg/kg/day
In this invention, the female mice were (BALB/cAnN.Cg-Foxn1nu/CrlNarl) purchased from National Laboratory Animal Center (Taiwan)). The weight of the mice were 21±1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “control group”, “low dose group (100 mg/kg/day)”, and “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm3. The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L×W2)/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment result is shown in Table 20.
According to the results in
According to the results in
Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only and various modifications and alterations might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.
This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092617 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2015/092617 | 10/23/2015 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/062265 | 4/28/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20120315304 | Westerhof | Dec 2012 | A1 |
| Number | Date | Country | |
|---|---|---|---|
| 20170304218 A1 | Oct 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62068298 | Oct 2014 | US |
